A phase I study of gemcitabine followed by cisplatin concurrent with whole pelvic radiation therapy in locally advanced cervical cancer: A Gynecologic Oncology Group study

Gynecologic Oncology

Volumn 107, Issue 2, 2007, Pages 274-279

  Rose, Peter G ^a   DeGeest, Koen ^b   McMeekin, Scott ^c   Fusco, Nancy ^d  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF OKLAHOMA   (United States)

^d UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Cervical cancer; Cisplatin; Gemcitabine

Indexed keywords

CISPLATIN; FLUOROURACIL; GEMCITABINE; NAVELBINE; PACLITAXEL; TOPOTECAN;

ADVANCED CANCER; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; LEUKOPENIA; LUNG EMBOLISM; MAXIMUM TOLERATED DOSE; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; UROGENITAL TRACT DISEASE; UTERINE CERVIX CANCER; WEIGHT REDUCTION; WHOLE BODY RADIATION;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; DRUG ADMINISTRATION SCHEDULE; FEASIBILITY STUDIES; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; PELVIS; RADIOTHERAPY, ADJUVANT; UNITED STATES; UTERINE CERVICAL NEOPLASMS;

EID: 35348815784     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2007.06.012     Document Type: Article

References (31)

1. Whitney C.W., Sause W., Bundy B.N., et al. A randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stages IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes. A Gynecologic Oncology Group and Southwest Oncology Group study. J. Clin. Oncol. 17 (1999) 1339-1348
2. Rose P.G., Bundy B.N., Watkins E.B., et al. Concurrent cisplatin-based chemoradiation improves progression free and overall survival in advanced cervical cancer: results of a randomized Gynecologic Oncology Group study. N. Engl. J. Med. 340 (1999) 1144-1153
3. Keys H.M., Bundy B.M., Stehman F.B., et al. A comparison of weekly cisplatin during radiation therapy versus irradiation alone each followed by adjuvant hysterectomy in bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group. N. Engl. J. Med. 340 (1999) 1154-1161
4. Morris M., Eifel P.J., Lu J., et al. Pelvic radiation with concurrent chemotherapy versus pelvic and para-aortic radiation for high risk cervical cancer: a randomized Radiation Therapy Oncology Group clinical trial. N. Engl. J. Med. 340 (1999) 1137-1143
5. Peters III W.A., Liu P.Y., Barrett R.J., et al. Cisplatin and 5-fluorouracil plus radiation therapy are superior to radiation therapy as adjunctive in high-risk early stage carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: report of a phase III intergroup study. J. Clin. Oncol. 18 (2000) 1606-1613
6. NCI Clinical Announcement, U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, February 1999.
7. Moore D.H., Blessing J.A., McQuellon R.P., et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J. Clin. Oncol. 22 (2004) 3113-3119
8. Long III H.J., Bundy B.N., Grendys Jr. E.C., et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J. Clin. Oncol. 23 (2005) 4626-4633
9. Lanciano R., Calkins A., Bundy B., et al. Randomized comparison of weekly cisplatin or protracted venous infusion of fluorouracil in combination with pelvic radiation in advanced cervix cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 23 (2005) 8289-8295
10. Huang P., and Plunkett W. Induction of apoptosis by gemcitabine. Semin. Oncol. 22 S11 (1995) 19-25
11. Hertel L.W., Boder G.B., Kroin J.S., et al. Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res. 50 (1990) 4417-4422
12. Abbruzzese J.L., Grunewald R., Weeks E.A., et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J. Clin. Oncol. 9 (1991) 491-498
13. Pollera C.F., Ceribelli A., Crecco M., et al. Weekly gemcitabine: a phase I study with short and prolonged infusion schedules. Proc. Am. Clin. Oncol. 11 (1992) 127
14. Brown T., O'Rourke T., Burris H., et al. A phase I trial of gemcitabine (LY 188011) administered intravenously every two weeks. Proc. Am. Soc. Clin. Oncol. 10 (1991) 115
15. Vermorken J.B., Guastalla J.P., Hatty S.R., et al. Phase I study of gemcitabine using a once every 2 weeks schedule. Br. J. Cancer 76 (1997) 1489-1493
16. Poplin E., Redmond B., Flaherty L., et al. Difluorodeoxycytidine (dFdC): a phase I study. Proc. Am. Assoc. Cancer Res. 30 (1989) 282
17. O'Rourke T.J., Brown T.D., Havlin K., et al. Phase I clinical trial of gemcitabine given as an intravenous bolus on 5 consecutive days. Eur. J. Cancer 30A (1994) 417-418
18. Schilder R.J., Blessing J.A., Morgan M., et al. Evaluation of gemcitabine in patients with squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol. Oncol. 76 (2000) 204-207
19. Peters G.J., Bergman A.M., Ruiz van Haperen V.W.T., et al. Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin. Oncol. 22 (1995) 72-79
20. Thodossiou C., Cook J.A., Fisher J., et al. Interaction of gemcitabine with paclitaxel and cisplatin in human tumor cell lines. Int. J. Oncol. 12 (1998) 825-832
21. Burnett A.F., Roman L.D., Garcia A.A., et al. A phase II study of gemcitabine and cisplatin in patients with advanced, persistent or recurrent squamous cell carcinoma of the cervix. Gynecol. Oncol. 76 (2000) 63-66
22. Lorvidhaya V., Kamnerdsupaphon P., Chitapanarux I., et al. Cisplatin and gemcitabine in patients with metastatic cervical cancer. Gan To Kagaku Ryoho 31 (2004) 1056-1057
23. Bouzid K, Mahfouf H. A study with gemcitabine (G) and cisplatin (C) in locally advanced, recurrent or metastatic squamous cell carcinoma of the cervix. Proc Am Soc Clin Oncol 19 (2000) 391a vs ASCO 22 (2003) A1900.
24. Mose S., Karapetian M., Juling-Pohlit L., et al. The intensification of the radiotherapeutic effect on HeLa cells by gemcitabine. Strahlenther. Onkol. 75 2 (1999) 78-83
25. Pattaranutaporn P., Thirapakawong C., Chansilpa Y., et al. Phase II study of concurrent gemcitabine and radiotherapy in locally advanced stage IIIB cervical carcinoma. Gynecol. Oncol. 81 (2001) 404-407
26. Zarba J.J., Jaremtchuk A.V., Gonzales Jazey P., et al. A phase I-II study of weekly cisplatin and gemcitabine with concurrent radiotherapy in locally advanced cervical cancer. Ann. Oncol. 14 (2003) 1285-1290
27. Umanzor J., Aguiluz M., Pineda C., et al. Concurrent cisplatin/gemcitabine along with radiotherapy in locally advanced cervical carcinoma: a phase II trial. Gynecol. Oncol. 100 (2006) 70-75
28. Duenes-Gonzales A., Cetina-Perez L., Lopez-Graniel C., et al. Pathologic response and toxicity assessment of chemoradiotherapy with cisplatin versus cisplatin plus gemcitabine in cervical cancer: a randomized phase II study. Int. J. Radiat. Oncol. Biol. Phys. 61 (2005) 817-823
29. Moufarij M.A., Phillips D.R., and Cullinane C. Gemcitabine potentiates cytotoxicity and inhibits repair of cisplatin-DNA damage in ovarian cancer cell lines. Mol. Pharmacol. 63 (2003) 862-869
30. Swisher E.M., Swensen R.E., Greer B., et al. Weekly gemcitabine and cisplatin in combination with pelvic radiation therapy in the primary treatment of cervical cancer: a phase I trial of the Puget Sound Oncology Consortium. Gynecol. Oncol. 101 (2006) 429-435
31. Kroep J.R., Peters G.J., van Moorsel C.J.A., et al. Gemcitabine-cisplatin: a schedule finding study. Ann. Oncol. 10 (1999) 1503-1510